Silver Book Fact

Cost of pneumonia vaccine

Addition of PCV13 (13-valent pneumococcal conjugate vaccine) to previously recommended pneumococcal polysaccharide vaccine for immunocompromised adults cost $70,937 per quality adjusted life year compared to no vaccine.

Smith K, Nowalk M, Raymund M, Zimmerman R. Cost-Effectiveness of Pneumococcal Conjugate Vaccination in Immunocompromised Adults. Vaccine. 2013; 31(37): 3950-6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742552/

Reference

Title
Cost-Effectiveness of Pneumococcal Conjugate Vaccination in Immunocompromised Adults
Publication
Vaccine
Publication Date
2013
Authors
Smith K, Nowalk M, Raymund M, Zimmerman R
Volume & Issue
Volume 31, Issue 37
Pages
3950-6
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Vaccines in development 2013
    Biopharmaceutical research companies are developing 271 vaccines for infectious diseases, cancer, neurological disorders, allergies, and other diseases.  
  • Staff vaccination in nursing homes reduces mortality rates of residents
    Mortality rates in nursing home residents were 42% lower in facilities with higher staff vaccination coverage compared with control facilities.  
  • Potential cost effectiveness of shingles vaccines
    The projected cost-effectiveness of a shingles vaccine for adults age 60 and older was estimated at $15,390 – $22,474 from the payer perspective, and $14,450 to $21,524 from the societal…  
  • Infection control program reduced hospital-acquired HAIs by > 1/3
    A multimodal infection control program reduced the rate of hospital-acquired HAIs by more than 1/3 and improved quality of care and patient outcomes.  
  • Over 6 years, flu vaccine prevented ~13 million cases
    Over a 6-year period (2005 – 2011), the influenza vaccine prevented an estimated 13 million influenza cases–between 1.1 million and 5 million annually.